| 1 |
NCT02015013 |
Recruiting |
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models |
- T-Lymphocytopenia, Idiopathic CD4-Positive
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
- to assess peripheral CD4 T cell and CD34 plus hematopoietic progenitor cell numbers and functions in ICL patients compared to controls following G-CSF and plerixafor administration.
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02015013 |
140020
14-I-0020 |
|
December 13, 2013 |
October 31, 2018 |
January 1, 2019 |
December 19, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 2 |
NCT00867269 |
Recruiting |
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia |
- Idiopathic CD4+ Lymphocytopenia
- Cryptococcal Meningitis
- Warts
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT00867269 |
090102
09-I-0102 |
|
March 19, 2009 |
|
|
March 23, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 3 |
NCT00001529 |
Recruiting |
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives |
- Graft vs Host Disease
- Healthy
- Lymphopenia
|
|
Interventional |
Phase 1 |
- National Heart, Lung, and Blood Institute (NHLBI)
- New York University and New York Genome Center
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Enumeration of laboratory studies using collected primitive hematopoietic cells and immune effector cells.
|
99999999 |
All |
18 Years to 60 Years (Adult) |
NCT00001529 |
960049
96-H-0049 |
|
March 14, 1996 |
May 1, 2030 |
May 1, 2030 |
November 4, 1999 |
April 13, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT01958515 |
Not yet recruiting |
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation |
- Head and Neck Cancer
- HPV (Human Papillomavirus)-Associated Carcinoma
- Oropharyngeal
|
- Other: research blood draw and tissue biopsy
|
Observational |
|
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Compare Systemic and Local Immunologic Changes During Chemoradiation
- Relationship of Radiotherapy-Related Lymphopenia and Changes in Cellular Immunity During Chemoradiation
|
20 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01958515 |
J13158
IRB00092006 |
|
March 2016 |
March 2019 |
|
October 9, 2013 |
January 15, 2016 |
|
- The Johns Hopkins SKCCC
Baltimore, Maryland, United States
|
| 5 |
NCT01905826 |
Recruiting |
Natural History Study of GATA2 Deficiency and Related Disorders |
- Myelodysplasia
- Monocytopenia
- B Cell Lymphopenia
- (and 2 more...)
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Baylor College of Medicine
- UCSF Diabetes Center and Division of Infectious Diseases
- (and 3 more...)
|
NIH / Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Characterize the full spectrum of clinical disease
- Better understand the reasons for Phenotypic variability
- Better understand the progression of disease
- (and 2 more...)
|
600 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01905826 |
130157
13-I-0157 |
|
July 18, 2013 |
March 1, 2028 |
January 1, 2030 |
July 23, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 6 |
NCT03394053 |
Recruiting |
The Mechanistic Biology of Primary Immunodeficiency Disorders |
- Primary Immunodeficiency Disorders
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identification of genetic variants that are associated with PID
- Identification of unique clinical phenotypes associated with known genetic causes of PID
- Identification of phenotypic, molecular, and functional abnormalities associated with known or novel forms of PID.
- (and 2 more...)
|
1100 |
All |
up to 75 Years (Child, Adult, Senior) |
NCT03394053 |
180041
18-I-0041 |
|
April 27, 2018 |
December 31, 2030 |
December 31, 2030 |
January 9, 2018 |
April 24, 2018 |
|
- Division of Allergy & Immunology Children's Hospital (CNHS)
Washington, District of Columbia, United States - National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 7 |
NCT03330795 |
Recruiting |
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant |
- Primary Immunodeficiency
- PID
|
- Biological: CD3/CD19 neg allogeneic BMT
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: Transplant-Related Mortality
- Safety: Engraftment Failure
- Efficacy: Count of Participants with Absence of Severe Allograft Dysfunction
- (and 18 more...)
|
8 |
All |
10 Years to 45 Years (Child, Adult) |
NCT03330795 |
DAIT BOLT-BMT
DAIT RTB-003
U01AI125050 |
BOLT-BMT |
November 21, 2017 |
November 2023 |
November 2024 |
November 6, 2017 |
November 24, 2017 |
|
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
|
| 8 |
NCT02179086 |
Recruiting |
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma |
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
|
- Radiation: 3-dimensional conformal radiation therapy
- Radiation: intensity-modulated radiation therapy
- Radiation: photon beam radiation therapy
- (and 3 more...)
|
Interventional |
Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) compared between dose-escalated and -intensified photon IMRT or proton beam therapy with concomitant and adjuvant temozolomide and the standard-dose photon irradiation with concomitant and adjuvant temozolomide
- OS when compared between dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy
- Progression-free survival (PFS)
- (and 5 more...)
|
606 |
All |
18 Years and older (Adult, Senior) |
NCT02179086 |
NRG-BN001
NCI-2014-01072
U10CA180868 |
|
October 27, 2014 |
May 2019 |
May 2024 |
July 1, 2014 |
January 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Arizona Oncology Associates-West Orange Grove
Tucson, Arizona, United States - (and 220 more...)
|
| 9 |
NCT01953016 |
Recruiting |
Participation in a Research Registry for Immune Disorders |
- Primary Immunodeficiencies
- GATA2
- CGD (Chronic Granulomatous Disease)
- (and 2 more...)
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
- We will add NHGRI patients enrolled in 00-HG-0209 into a national registry of individuals with primary immune deficiency disorders to discover basic outcome data, ethnic and racial characteristics, kinds of complications etc. of these immune def...
|
1000 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT01953016 |
130199
13-HG-0199 |
|
September 25, 2013 |
May 1, 2020 |
May 1, 2020 |
September 30, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 10 |
NCT02064933 |
Recruiting |
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary Immune Deficiency Treatment Consortium
- Rare Diseases Clinical Research Network
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Longitudinal Analysis: Overall Survival From Time of HCT/Gene Therapy
- Cross-Sectional Analysis: Proportion of Participants Achieving Full T Cell Reconstitution
- Cross-Sectional Analysis: Proportion of Participants Achieving Full B Cell Reconstitution
- (and 28 more...)
|
541 |
Male |
Child, Adult, Senior |
NCT02064933 |
DAIT RDCRN PIDTC-6904 |
|
June 2014 |
August 2019 |
August 2019 |
February 17, 2014 |
October 17, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - (and 41 more...)
|
| 11 |
NCT03333486 |
Recruiting |
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Leukemia in Remission
- Acute Lymphoblastic Leukemia
- (and 34 more...)
|
- Drug: Cyclophosphamide
- Drug: Fludarabine Phosphate
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse rate
- Engraftment rate
- Incidence of acute graft versus host disease (GVHD)
- (and 4 more...)
|
58 |
All |
1 Year to 75 Years (Child, Adult, Senior) |
NCT03333486 |
I 40916
NCI-2017-01949
P30CA016056 |
|
December 7, 2017 |
September 6, 2021 |
September 6, 2022 |
November 7, 2017 |
December 11, 2017 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: